Injection drug use is the primary driver of hepatitis C virus infection in North America and Europe, with seroprevalence among people who inject drugs ranging from 18% to 88%.
Read More > https://hepatitisc.pocn.com/patient-management/expanding-hepatitis-c-virus-care-for-people-who-inject-drugs/
